PTPRF - New-wiki

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
JUP	junction plakoglobin	Adherens junctions interactions VEGFR2 mediated vascular permeability Neutrophil degranulation Keratinization Formation of the cornified envelope RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RHOQ GTPase cycle RHOH GTPase cycle RHOJ GTPase cycle Regulation of CDH11 function Regulation of CDH11 function Regulation of CDH19 Expression and Function Regulation of CDH1 Function Degradation of CDH1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane CDH11 homotypic and heterotypic interactions	Zinc Zinc acetate	Naxos disease and Carvajal syndrome Arrhythmogenic right ventricular cardiomyopathy (ARVC)
LACTB	lactamase beta
LCK	LCK proto-oncogene, Src family tyrosine kinase	GPVI-mediated activation cascade PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Nef and signal transduction Nef Mediated CD4 Down-regulation Downstream TCR signaling Phosphorylation of CD3 and TCR zeta chains Translocation of ZAP-70 to Immunological synapse Generation of second messenger molecules PECAM1 interactions Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling DAP12 signaling Co-stimulation by CD28 CD28 dependent PI3K/Akt signaling CD28 dependent Vav1 pathway Co-inhibition by CTLA4 Co-inhibition by PD-1 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RHOH GTPase cycle Interleukin-2 signaling Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants FLT3 signaling through SRC family kinases	Dasatinib AP-22408 Staurosporine 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine {4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid Phosphoaminophosphonic Acid-Adenylate Ester 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine Ponatinib Nintedanib Fostamatinib Zanubrutinib Zotiraciclib	Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
LDHA	lactate dehydrogenase A	Pyruvate metabolism Regulation of pyruvate metabolism	NADH Etheno-NAD Nicotinamide Oxamic Acid Stiripentol Copper Artenimol
LDHB	lactate dehydrogenase B	Pyruvate metabolism	NADH 4-Hydroxy-1,2,5-oxadiazole-3-carboxylic acid Oxamic Acid Stiripentol Artenimol
NCAN	neurocan	Glycosaminoglycan-protein linkage region biosynthesis CS-GAG biosynthesis DS-GAG biosynthesis CS/DS degradation ECM proteoglycans Defective B4GALT7 causes EDS, progeroid type Defective B3GAT3 causes JDSSDHD Defective CHST3 causes SEDCJD Defective CHST14 causes EDS, musculocontractural type Defective CHSY1 causes TPBS L1CAM interactions NCAM1 interactions Defective B3GALT6 causes EDSP2 and SEMDJL1	Beta-D-Glucose Thiodigalactoside Hyaluronic acid
NID1	nidogen 1	Degradation of the extracellular matrix Degradation of the extracellular matrix Laminin interactions Laminin interactions	Urokinase
OMG	oligodendrocyte myelin glycoprotein	Axonal growth inhibition (RHOA activation)
PPFIA1	PPFI scaffold protein A1	Serotonin Neurotransmitter Release Cycle Norepinephrine Neurotransmitter Release Cycle Glutamate Neurotransmitter Release Cycle Dopamine Neurotransmitter Release Cycle Acetylcholine Neurotransmitter Release Cycle Receptor-type tyrosine-protein phosphatases
PPFIA2	PPFI scaffold protein A2	Serotonin Neurotransmitter Release Cycle Norepinephrine Neurotransmitter Release Cycle Glutamate Neurotransmitter Release Cycle Dopamine Neurotransmitter Release Cycle Acetylcholine Neurotransmitter Release Cycle Receptor-type tyrosine-protein phosphatases
PPFIA3	PPFI scaffold protein A3	Serotonin Neurotransmitter Release Cycle Norepinephrine Neurotransmitter Release Cycle Glutamate Neurotransmitter Release Cycle Dopamine Neurotransmitter Release Cycle Acetylcholine Neurotransmitter Release Cycle Receptor-type tyrosine-protein phosphatases
PRPF40A	pre-mRNA processing factor 40A	mRNA Splicing - Major Pathway
PTPRA	protein tyrosine phosphatase receptor type A	NCAM signaling for neurite out-growth NCAM signaling for neurite out-growth RAF/MAP kinase cascade
PTPRD	protein tyrosine phosphatase receptor type D	Receptor-type tyrosine-protein phosphatases Synaptic adhesion-like molecules
PTPRZ1	protein tyrosine phosphatase receptor type Z1	Other interleukin signaling MDK and PTN in ALK signaling
RAP1GDS1	Rap1 GTPase-GDP dissociation stimulator 1	RHOT2 GTPase cycle RHOT1 GTPase cycle
RET	ret proto-oncogene	RAF/MAP kinase cascade RET signaling NPAS4 regulates expression of target genes Formation of the nephric duct Formation of the ureteric bud	Sorafenib 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine Vandetanib Cabozantinib Regorafenib Ponatinib Lenvatinib Fostamatinib Amuvatinib Selpercatinib Pralsetinib	Congenital central hypoventilation syndrome (CCHS) Hirschsprung disease (HD) Thyroid cancer Renal agenesis and Renal adysplasia
RHOA	ras homolog family member A	GPVI-mediated activation cascade Axonal growth inhibition (RHOA activation) PI3K/AKT activation Axonal growth stimulation TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) G beta:gamma signalling through PI3Kgamma EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse PCP/CE pathway G alpha (12/13) signalling events Sema4D mediated inhibition of cell attachment and migration Sema4D induced cell migration and growth-cone collapse Sema4D induced cell migration and growth-cone collapse VEGFA-VEGFR2 Pathway RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases activate CIT RHO GTPases activate KTN1 RHO GTPases Activate ROCKs RHO GTPases Activate ROCKs RHO GTPases Activate Formins RHO GTPases Activate Rhotekin and Rhophilins RHO GTPases Activate Rhotekin and Rhophilins Ovarian tumor domain proteases ERBB2 Regulates Cell Motility Neutrophil degranulation PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases RHOA GTPase cycle SLIT2:ROBO1 increases RHOA activity RHOC GTPase cycle	Guanosine-5'-Diphosphate
ROCK2	Rho associated coiled-coil containing protein kinase 2	EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse G alpha (12/13) signalling events Sema4D induced cell migration and growth-cone collapse Sema4D induced cell migration and growth-cone collapse VEGFA-VEGFR2 Pathway RHO GTPases Activate ROCKs RHO GTPases Activate ROCKs RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle RHOH GTPase cycle RHOBTB1 GTPase cycle Potential therapeutics for SARS	Fasudil Y-27632 Fostamatinib Ripasudil Netarsudil Belumosudil
SEMG1	semenogelin 1	Antimicrobial peptides Amyloid fiber formation	Zinc Zinc acetate Zinc chloride Zinc sulfate, unspecified form

Search Results for: PTPRF